• 제목/요약/키워드: small-cell lung cancer

검색결과 1,136건 처리시간 0.024초

A 항원 양성 원발성 비소세포폐암 조직에서의 A 항원 소실과 생존기간과의 관계 (The Relationship Between Loss of Blood Group Antigen A in Cancer Tissue and Survival Time in the Antigen A Positive Non-Small Cell Lung Cancer)

  • 양세훈;정은택
    • Tuberculosis and Respiratory Diseases
    • /
    • 제48권3호
    • /
    • pp.339-346
    • /
    • 2000
  • 연구배경 : 혈액형 A 항원의 발현은 적혈구외에 비뇨기, 위장, 폐, 구강점막 동의 상피세포에도 존재한다. 조직 손상 치유 과정 중 인접 상피세포는 혈액형 A 항원이 소실되고, 상처가 치유되면 혈액형 A 항원은 다시 발현된다. 방광암등의 조직에서도 혈액형 A 항원이 소실될 경우가 발현유지 되는 경우보다 종양의 증식이 활발하다고 보고하였다. 또한 수술한 비소세포폐암의 조직에서 혈액형 A 항원이 소실될 경우 생존율은 불량하다고 보고하였다. 그러나, 이에 반하는 보고도 다수 있어 저자들은 근치적 절제술을 시행 받은 말초 혈액형이 A, AB형인 비소세포폐암에서 혈액형 A항원의 소실여부와 생존율과의 관계를 검색하였다. 대상 및 방법 : 원발성 비소세포폐암으로 진단 받은 후 근치 목적의 절제술을 받았던 환자 76명중 혈액형이 A형, 또는 AB형인 26명을 대상으로 paraffin에 보관된 조직을 면역조직화학염색법을 이용하여 혈액형 A항원의 소실유무을 확인한 후, 발현 및 소실에 따른 생존율은 Kaplan-Meier법, Log-rank로서 검색하였다. 결 과 : 대상군은 26례(A형 : 22례, AB형 : 4례)로 남 : 녀는 20 : 6이었고, 평균연령은 63세였으며, 조직학적으로 편평상피암 16례, 선암 6례, 대세포암 4례였고, TNM병기는 I 16례, II 5례, IIIA 5례였다. 종양조직에서 A항원 발현유지는 15례(58%), A 항원 소실은 11례(42%)였으며, A 항원 발현율과 병리조직형, 조직의 분화도와는 상관관계가 없었다. A항원 발현유지군과 소실군간의 중간 생존기간은 11개월, 18개월이며, 2년 생존률은 36%, 64%로서 A 항원 소실군의 예후가 양호하였으나, 통계적으로 유의한 차이는 없었다. 결 론 : 원발성 비소세포폐암으로 절제수술을 받았던 혈액형이 A형, 또는 AB형인 환자중 조직에서의 A 항원소실은 42%이었고, A항원 소실군이 발현유지군보다 생존율이 길었으나 예후인자로서의 유의성은 찾지 못했다.

  • PDF

소세포성 폐암과 연관된 망막증 1예 (A Case of Cancer Associated Retinopathy with Small Cell Lung Carcinoma)

  • 임성민;배종오;조상건;강상구;이은영;김성국;김영;곽진영;김귀완
    • Tuberculosis and Respiratory Diseases
    • /
    • 제59권6호
    • /
    • pp.679-683
    • /
    • 2005
  • 저자들은 시야 결손 등의 시력 변화를 주 증상으로 내원한 환자에서 소세포 폐암과 이로 인한 부종양성증후군으로 동반된 암 관련 망막증을 진단하고 항암화학요법을 시행하여, 원발 병변의 부분 관해 보였으나, 시야 결손은 회복되지 않았던 1예를 경험하였기에 문헌 고찰과 함께 보고 하는 바이다.

Association of Methylation of the RAR-β Gene with Cigarette Smoking in Non-Small Cell Lung Cancer with Southern-central Chinese Population

  • Li, Wen;Deng, Jing;Wang, Shuang-Shuang;Ma, Liang;Pei, Jiang;Zeng, Xiao-Xi;Tang, Jian-Xin
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제15권24호
    • /
    • pp.10937-10941
    • /
    • 2015
  • Pathogenesis of lung cancer is a complicated biological process including multiple genetic and epigenetic changes. Since cigarette smoking is confirmed as the most main risk factor of non-small cell lung cancer (NSCLC), the aim of this study was to determine whether tobacco exposure plays a role in gene methylation. Methylation of the RAR-${\beta}$ gene were detected using methylation-specific polymerase chain reaction in DNA from 167 newly diagnosed cases with NSCLC and corresponding 105 controls. A significant statistical association was found in the detection rate of the promoter methylation of RAR-${\beta}$ gene between NSCLC and controls ($x^2$=166.01; p<0.01), and hypermethylation of the RAR-${\beta}$ gene was significantly associated with smoking status (p=0.038, p<0.05). No relationship was found between RAR-${\beta}$ gene methylation and pathologic staging including clinical stage, cell type, gender and drinking (p>0.05), and the methylation of RAR-${\beta}$ gene rate of NSCLC was slightly higher in stages III+IV (80.0%) than in I+II (70.8%). Similar results were obtained for methylation of the RAR-${\beta}$ gene between squamous cell carcinoma (77.9%) and other cell type lung cancer (73.9%). These results showed that the frequency of methylation increased gradually with the development of clinical stage in smoking-associated lung cancer patients, and tobacco smoke may be play a potential role in RAR-${\beta}$ gene methylation in the early pathogenesis and process in lung cancer, particularly squamous cell carcinoma. Aberrant promoter methylation is considered to be a promising marker of previous carcinogen exposure and cancer risk.

Newly Developed Weakness of Lower Extremities Despite Improved Brain Metastasis of Lung Cancer after Radiotherapy

  • Yang, Jae Hyun;Jang, Young Joo;Ahn, Se Jin;Kim, Hye-Ryoun;Kim, Cheol Hyeon;Koh, Jae Soo;Choe, Du Hwan;Lee, Jae Cheol
    • Tuberculosis and Respiratory Diseases
    • /
    • 제67권6호
    • /
    • pp.574-576
    • /
    • 2009
  • An intramedullary spinal cord metastasis (ISCM) rarely develops in systemic cancer but is indicative of a poor prognosis. A 56-year-old man was admitted due to weakness of the lower extremities. He had received radiotherapy 3 months prior for a brain metastasis that had developed 1 year after achieving a complete response from chemotherapy for extended stage small cell lung cancer. Although the brain lesion had improved partially, ISCM from the cervical to lumbar-sacral spinal cords, which was accompanied by a leptomeningeal dissemination, was diagnosed based on magnetic resonance imaging of the spine and cerebrospinal fluid cytology. Finally, he died of sudden cardiac arrest during treatment. This is the first case of ISCM involving the whole spinal segments. Physicians should be aware of the subsequent development of ISCM in lung cancer patients with a previously known brain metastasis who present with new neurological symptoms.

Cavernous Sinus Metastasis of Non-Small Cell Lung Cancer

  • Ahn, Young;Yang, Jae-Hyun;Kim, Hyung-Jin;Jang, Sang-Eon;Jang, Young-Joo;Kim, Hye-Ryoun;Kim, Cheol-Hyeon;Choi, Sang-Yul;Lee, Jae-Cheol
    • Tuberculosis and Respiratory Diseases
    • /
    • 제69권5호
    • /
    • pp.381-384
    • /
    • 2010
  • Progressive ptosis and headache developed in a 50-year-old woman with non-small cell lung cancer. Although brain magnetic resonance imaging showed improved cerebellar metastasis after prior radiotherapy without any other abnormality, the follow-up examination taken 6 months later revealed metastasis to the cavernous sinus. The diagnosis of metastasis to the cavernous sinus is often difficult because it is a very rare manifestation of lung cancer, and symptoms can occur prior to developing a radiologically detectable lesion. Therefore, when a strong clinical suspicion of cavernous sinus metastasis exists, thorough neurologic examination and serial brain imaging should be followed up to avoid overlooking the lesion.

Clinical Validation of a Protein Biomarker Panel for Non-Small Cell Lung Cancer

  • Jung, Young Ju;Oh, In-Jae;Kim, Youndong;Jung, Jong Ha;Seok, Minkyoung;Lee, Woochang;Park, Cheol Kyu;Lim, Jung-Hwan;Kim, Young-Chul;Kim, Woo-Sung;Choi, Chang-Min
    • Journal of Korean Medical Science
    • /
    • 제33권53호
    • /
    • pp.342.1-342.6
    • /
    • 2018
  • We validated the diagnostic performance of a previously developed blood-based 7-protein biomarker panel, $AptoDetect^{TM}$-Lung (Aptamer Sciences Inc., Pohang, Korea) using modified aptamer-based proteomic technology for lung cancer detection. Non-small cell lung cancer (NSCLC), 200 patients and benign nodule controls, 200 participants were enrolled. In a high-risk population corresponding to ${\geq}55years$ of age and ${\geq}30pack-years$, the diagnostic performance was improved, showing 73.3% sensitivity and 90.5% specificity with an area under the curve of 0.88. $AptoDetect^{TM}$-Lung (Aptamer Sciences Inc.) offers the best validated performance to discriminate NSCLC from benign nodule controls in a high-risk population and could play a complementary role in lung cancer screening.

Multidisciplinary team approach for the management of patients with locally advanced non-small cell lung cancer: searching the evidence to guide the decision

  • Oh, In-Jae;Ahn, Sung-Ja
    • Radiation Oncology Journal
    • /
    • 제35권1호
    • /
    • pp.16-24
    • /
    • 2017
  • Locally advanced non-small cell lung cancer (LA-NSCLC) is composed of heterogeneous subgroups that require a multidisciplinary team approach in order to ensure optimal therapy for each patient. Since 2010, the National Comprehensive Cancer Network has recommended chemoradiation therapy (CRT) for bulky mediastinal disease and surgical combination for those patients with single-station N2 involvement who respond to neoadjuvant therapy. According to lung cancer tumor boards, thoracic surgeons make a decision on the resectability of the tumor, if it is determined to be unresectable, concurrent CRT (CCRT) is considered the next choice. However, the survival benefit of CCRT over sequential CRT or radiotherapy alone carries the risk of additional toxicity. Considering severe adverse events that may lead to death, fit patients who are able to tolerate CCRT must be identified by multidisciplinary tumor board. Decelerated approaches, such as sequential CRT or high-dose radiation alone may be a valuable alternative for patients who are not eligible for CCRT. As a new treatment strategy, investigators are interested in the application of the innovative radiation techniques, trimodality therapy combining surgery after high-dose definitive CCRT, and the combination of radiation with targeted or immunotherapy agents. The updated results and on-going studies are thoroughly reviewed in this article.

Clinicopathological Characteristics of Iranian Patients with Lung Cancer: a Single Institute Experience

  • Adnan, Khosravi;Zahra, Esfahani-Monfared;Sharareh, Seifi;Shirin, Karimi;Habib, Emami;Kian, Khodadad
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제17권8호
    • /
    • pp.3817-3822
    • /
    • 2016
  • Background: Lung cancer has long been a leading cause of cancer related death in both women and men worldwide. The focus of this study was to review clinicopathological features of Iranian patients diagnosed with lung cancer. Materials and Methods: Clinicopathological data of 1353 primary lung cancer patients diagnosed during 17 years (1997-2014) in the "National Institute of Tuberculosis and Lung Disease" (NRITLD), Tehran, Iran, were retrospectively reviewed. Results: The median age of patients was 60 (mean: 58.95 years, range: 16-99) and adenocarcinoma was the most prevalent pathology (45.2%). Male/female ratio was 3.22 and 57.2% of patients were smokers (men 70.3%, women 15%). The majority (85.3%) were referred in advanced stages (stage IIIB and IV). Conclusions: Although some of our findings are in concordance with other studies in lung cancer but there are some discrepancies particularly in terms of smoking status and median age of Iranian patients. Further clinical and epidemiological studies are warranted to elucidate etiologic and factors other than smoking contributing to development of lung cancer such as environmental exposures or genetic predisposition.

비소세포성폐암 환자의 $Monototal^{TM}$ 유용성 평가 (Evaluation of Usefulness for $Monototal^{TM}$ in Non Small Cell Lung Cancer)

  • 김대운;서효열;장현영;노경운;김현주
    • 핵의학기술
    • /
    • 제13권3호
    • /
    • pp.171-174
    • /
    • 2009
  • 목적 : 2008년도 국내에서의 암 사망원인 1위가 폐암이며, 폐암으로 인한 사망자수는 매년 증가 하고 있다. 이 폐암은 대부분이 진행된 상태로 발견되면 이들 중 80%는 비소세포 성폐암(NSCLC)이다. 종양표지자 검사는 질병의 진행과 관련된 신뢰성 있는 결과를 신속히 의료진에게 제공해야 하는데 $Monototal^{TM}$ 검사는 반응시간이 짧으며, 비소세포성폐암 특히, Squamous cell(편평상피세포)에 대한 예민도가 높은 검사로 알려져 있다. 이에 비소세포성폐암의 진단 및 치료경과 관리를 위한 새로운 종양표지자인 $Monototal^{TM}$의 임상적 유용성에 대해 알아보고자 한다. 실험재료 및 방법 : 2009년 3월에서 4월까지 본원에 의뢰된 비소세포성폐암 환자 검체중 CEA가 양성인 검체 48건과 SCC 양성인 검체 15건, CYFRA 21-1 양성 검체 40건과 음성검체 20건을 대상으로 $Monototal^{TM}$을 측정하여 결과를 비교 하였다. 결과 : 비소세포성폐암 진단받은 환자 검체의 87.5%가 $Monototal^{TM}$ 검사에서 양성을 보였다. SCC 양성인 검체에서는 93.3%양성을 보였다. CYFRA 21-1 양성 검체에서는 100%의 양성을 보였고 음성인 검체에서도 50%의 양성을 보였다. 결론 : 종양표지자는 임상적으로 치료 후 환자의 경과 관찰에 유용하게 사용 되므로 중요하다. 실험 결과 비소세포성폐암에서 $Monototal^{TM}$의 양성률이 높게 보고 되었다. $Monototal^{TM}$의 임상적 가치를 평가 하기 위해서는 좀더 많은 검사가 필요하다고 생각한다. 그러나 CYFRA 21-1 보다 짧은 시간에 결과를 보고 할 수 있고 높은 양성률을 보인 것으로 보아 임상적으로 의의가 있다고 판단된다. 따라서 다른 종양표지자와 병행해서 검사하면 폐암의 진단과 예후 추정에 있어서 임상적으로 유용하다고 생각된다.

  • PDF

Video-Assisted Thoracic Surgery Mediastinal Lymph Node Dissection in Lung Cancer Surgery

  • Kim, Kwhanmien
    • Journal of Chest Surgery
    • /
    • 제54권4호
    • /
    • pp.258-262
    • /
    • 2021
  • Mediastinal lymph node dissection is an important part of lung cancer surgery that provides accurate nodal staging and may improve survival outcomes. The minimally invasive approach, such as video-assisted thoracic surgery (VATS) lobectomy for patients with non-small cell lung cancer, has become a standard operation worldwide. VATS mediastinal lymph node dissection should be thorough and accurate to ensure the completeness of lung cancer surgery. Herein, the author describes techniques for VATS mediastinal lymph node dissection.